Journal
VIRUSES-BASEL
Volume 11, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/v11010028
Keywords
CRISPR; viral vectors; gene therapy; animal models; gene editing
Categories
Funding
- Jonas Children's Vision Care and Bernard & Shirlee Brown Glaucoma Laboratory
- National Institutes of Health [P30EY019007, R01EY018213, R01EY024698, R01EY026682, R21AG050437, R24EY027285]
- National Cancer Institute Core [5P30CA013696]
- Foundation Fighting Blindness [TA-NMT-0116-0692-COLU]
- Research to Prevent Blindness (RPB) Physician-Scientist Award
- RPB, New York, NY, USA
- Kobi and Nancy Karp
- Crowley Family Fund
- Rosenbaum Family Foundation
- Tistou and Charlotte Kerstan Foundation
- Schneeweiss Stem Cell Fund, New York State [C029572]
- Gebroe Family Foundation
Ask authors/readers for more resources
The frontiers of precision medicine have been revolutionized by the development of Clustered Regularly-Interspaced Short Palindromic Repeats (CRISPR)/Cas9 as an editing tool. CRISPR/Cas9 has been used to develop animal models, understand disease mechanisms, and validate treatment targets. In addition, it is regarded as an effective tool for genome surgery when combined with viral delivery vectors. In this article, we will explore the various viral mechanisms for delivering CRISPR/Cas9 into tissues and cells, as well as the benefits and drawbacks of each method. We will also review the history and recent development of CRISPR and viral vectors and discuss their applications as a powerful tool in furthering our exploration of disease mechanisms and therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
